Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients With Metastatic Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Breast Cancer

NCT06678269 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT06678269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06678269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Concurrent Abemaciclib and Radiation Therapy (RT) for Patients With Metastatic Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Breast Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
November 15, 2024
Completion date
November 30, 2028
Enrollment
28 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer metastatic, breast cancer stage iv, her2 negative breast carcinoma, her2-negative breast cancer, hormone-receptor-positive breast cancer, metastatic breast cancer, stage iv breast cancer